Table 3.
Comparison of survival and toxicities across the three major positive clinical trials in advanced pancreatic cancer
| Gemcitabine vs gemcitabine/erlotinib Phase III trial | ACCORD 11 trial | MPACT | ||||
|---|---|---|---|---|---|---|
| Gemcitabine | Gemcitabine/erlotinib | Gemcitabine | FOLFIRINOX | Gemcitabine | Gemcitabine/nab-paclitaxel | |
| Median OS | 5.91 mo | 6.24 mo | 6.8 mo | 11.1 mo | 6.7 mo | 8.5 mo |
| ORR | 8% | 8.6% | 9.4% | 31.6% | 7% | 23% |
| Toxicity | ||||||
| Neutropenia | – | – | 21% | 45.7% | 27% | 38% |
| Febrile neutropenia | – | – | 1.2% | 5.4% | 1% | 3% |
| Diarrhea | 2% | 6% | 1.8% | 12.7% | 1% | 6% |
| Sensory neuropathy | – | – | 0% | 9% | 1% | 17% |
| Fatigue | 15% | 15% | 17.8% | 23.6% | 7% | 17% |